5DT.F ENTERA BIO IS-0000769

Healthcare Biotechnology Frankfurt Exchange
2.80 EUR
Close of Nov 11, 2026
0.8400 3.46
Market cap
EUR 488M
P/E
-
P/B
75.21x
ROE
-297.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5DT.F undervalued?

Graham number

The Graham number of ENTERA BIO IS-0000769 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ENTERA BIO IS-0000769 fundamental analysis

No fundamental analysis for ENTERA BIO IS-0000769 yet.

ENTERA BIO IS-0000769 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ENTERA BIO IS-0000769

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the tre…

Full company profile